BAX vs. MRNA: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BAX and MRNA, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | BAX | MRNA |
|---|---|---|
| Company Name | Baxter International Inc. | Moderna, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Equipment & Supplies | Biotechnology |
| Market Capitalization | 12.38 billion USD | 10.46 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | October 27, 1981 | December 7, 2018 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of BAX and MRNA by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BAX | MRNA |
|---|---|---|
| 5-Day Price Return | 2.42% | 1.05% |
| 13-Week Price Return | -24.37% | 4.63% |
| 26-Week Price Return | -21.75% | -19.99% |
| 52-Week Price Return | -34.71% | -66.92% |
| Month-to-Date Return | 10.80% | -9.03% |
| Year-to-Date Return | -17.32% | -35.33% |
| 10-Day Avg. Volume | 14.95M | 9.93M |
| 3-Month Avg. Volume | 5.66M | 10.26M |
| 3-Month Volatility | 53.59% | 56.65% |
| Beta | 0.58 | 2.04 |
Profitability
Return on Equity (TTM)
BAX
-2.12%
Health Care Equipment & Supplies Industry
- Max
- 34.53%
- Q3
- 19.38%
- Median
- 9.52%
- Q1
- 4.86%
- Min
- -7.58%
BAX has a negative Return on Equity of -2.12%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
MRNA
-27.46%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
MRNA has a negative Return on Equity of -27.46%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
BAX
-1.42%
Health Care Equipment & Supplies Industry
- Max
- 23.34%
- Q3
- 13.06%
- Median
- 9.53%
- Q1
- 5.96%
- Min
- -3.87%
BAX has a negative Net Profit Margin of -1.42%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
MRNA
-94.31%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
MRNA has a negative Net Profit Margin of -94.31%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
BAX
-0.28%
Health Care Equipment & Supplies Industry
- Max
- 29.44%
- Q3
- 17.80%
- Median
- 13.95%
- Q1
- 8.73%
- Min
- -3.56%
BAX has a negative Operating Profit Margin of -0.28%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
MRNA
-106.34%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
MRNA has a negative Operating Profit Margin of -106.34%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | BAX | MRNA |
|---|---|---|
| Return on Equity (TTM) | -2.12% | -27.46% |
| Return on Assets (TTM) | -0.65% | -21.24% |
| Net Profit Margin (TTM) | -1.42% | -94.31% |
| Operating Profit Margin (TTM) | -0.28% | -106.34% |
| Gross Profit Margin (TTM) | 36.01% | 68.32% |
Financial Strength
Current Ratio (MRQ)
BAX
2.30
Health Care Equipment & Supplies Industry
- Max
- 4.90
- Q3
- 3.05
- Median
- 2.14
- Q1
- 1.49
- Min
- 0.86
BAX’s Current Ratio of 2.30 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.
MRNA
3.93
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
MRNA’s Current Ratio of 3.93 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
BAX
1.30
Health Care Equipment & Supplies Industry
- Max
- 1.49
- Q3
- 0.71
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
BAX’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 1.30. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
MRNA
0.01
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
MRNA’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
BAX
0.20
Health Care Equipment & Supplies Industry
- Max
- 58.29
- Q3
- 25.56
- Median
- 9.06
- Q1
- 3.60
- Min
- -28.92
BAX’s Interest Coverage Ratio of 0.20 is a critical concern. A value below 1.0 means operating earnings are insufficient to cover interest expenses, indicating severe financial strain and high default risk.
MRNA
--
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
Interest Coverage Ratio data for MRNA is currently unavailable.
Financial Strength at a Glance
| Symbol | BAX | MRNA |
|---|---|---|
| Current Ratio (MRQ) | 2.30 | 3.93 |
| Quick Ratio (MRQ) | 1.20 | 3.59 |
| Debt-to-Equity Ratio (MRQ) | 1.30 | 0.01 |
| Interest Coverage Ratio (TTM) | 0.20 | -- |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BAX
3.79%
Health Care Equipment & Supplies Industry
- Max
- 4.05%
- Q3
- 1.76%
- Median
- 0.71%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 3.79%, BAX offers a more attractive income stream than most of its peers in the Health Care Equipment & Supplies industry, signaling a strong commitment to shareholder returns.
MRNA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
BAX
90.20%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 72.47%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
BAX’s Dividend Payout Ratio of 90.20% is in the upper quartile for the Health Care Equipment & Supplies industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
MRNA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | BAX | MRNA |
|---|---|---|
| Dividend Yield (TTM) | 3.79% | 0.00% |
| Dividend Payout Ratio (TTM) | 90.20% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
BAX
--
Health Care Equipment & Supplies Industry
- Max
- 73.48
- Q3
- 51.69
- Median
- 34.31
- Q1
- 25.74
- Min
- 11.47
P/E Ratio data for BAX is currently unavailable.
MRNA
--
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for MRNA is currently unavailable.
Price-to-Sales Ratio (TTM)
BAX
1.14
Health Care Equipment & Supplies Industry
- Max
- 9.53
- Q3
- 5.26
- Median
- 3.39
- Q1
- 2.13
- Min
- 0.00
In the lower quartile for the Health Care Equipment & Supplies industry, BAX’s P/S Ratio of 1.14 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
MRNA
3.42
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
In the lower quartile for the Biotechnology industry, MRNA’s P/S Ratio of 3.42 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
BAX
2.12
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 5.98
- Median
- 3.48
- Q1
- 2.43
- Min
- 0.69
BAX’s P/B Ratio of 2.12 is in the lower quartile for the Health Care Equipment & Supplies industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
MRNA
1.14
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
MRNA’s P/B Ratio of 1.14 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | BAX | MRNA |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | -- |
| Price-to-Sales Ratio (TTM) | 1.14 | 3.42 |
| Price-to-Book Ratio (MRQ) | 2.12 | 1.14 |
| Price-to-Free Cash Flow Ratio (TTM) | 18.65 | 34.70 |